As filed with the Securities and Exchange Commission on January 30, 2026 Registration No. 333-290302 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LYTUS TECHNOLOGIES HOLDINGS PTV. LTD. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 7841 Not applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) ...

As filed with the Securities and Exchange Commission on December 30, 2025 Registration No. 333-290302 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LYTUS TECHNOLOGIES HOLDINGS PTV. LTD. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 7841 Not applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number ...

As filed with the Securities and Exchange Commission on December 10, 2025 Registration No. 333- 290302 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LYTUS TECHNOLOGIES HOLDINGS PTV. LTD. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 7841 Not applicable (I.R.S. Employer Identification Number) (State or Other Jurisdiction of Incorporation or Organization) Classification ...

Core Insights - PureTech Health plc announced the successful completion of the End-of-Phase 2 meeting with the FDA regarding deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis (IPF) treatment [1][2] - The Phase 3 SURPASS-IPF trial will compare deupirfenidone 825 mg three times a day to pirfenidone 801 mg three times a day, with a primary efficacy endpoint of change in absolute forced vital capacity (FVC) at week 52 [2][3] - Deupirfenidone has shown a slower rate of lung function decline in the Phase 2b ELEVATE IPF trial, with a 91 mL difference in FVC decline compared to placebo at 26 weeks [3][6] Company Overview - PureTech Health is a biotherapeutics company focused on transforming innovation into value through a capital-efficient R&D model [11] - Celea Therapeutics, a subsidiary of PureTech, is dedicated to advancing treatments for serious respiratory diseases, with deupirfenidone as its lead program [9][10] Clinical Development - The Phase 3 SURPASS-IPF trial is set to begin in the first half of 2026, with financing expected to be finalized by early 2026 [4] - The ELEVATE IPF trial demonstrated that deupirfenidone maintained a favorable safety profile while stabilizing lung function decline over at least 26 weeks [6] Market Context - Deupirfenidone is positioned as a next-generation antifibrotic and a potential new standard of care for IPF, addressing limitations of existing therapies [5][6] - Historically, only about 25% of IPF patients in the U.S. have received treatment, indicating a significant unmet need in the market [5]

Core Insights - PureTech's founded entity Gallop Oncology has announced positive initial topline data for LYT-200 in the treatment of relapsed/refractory acute myeloid leukemia [1] Group 1 - The initial data indicates that LYT-200 shows promise in addressing relapsed/refractory acute myeloid leukemia, a condition with significant unmet medical needs [1] - The announcement highlights the potential of LYT-200 to improve patient outcomes in a challenging therapeutic area [1]

Core Insights - PureTech has presented new data from the Phase 2b open-label extension study of Deupirfenidone, indicating its potential to become a new standard of care for Idiopathic Pulmonary Fibrosis (IPF) [1] Group 1: Study Findings - The data supports the efficacy and safety profile of Deupirfenidone in treating IPF, suggesting significant clinical benefits [1] - The study results demonstrate a favorable outcome in terms of lung function preservation and quality of life for patients [1] Group 2: Market Implications - If approved, Deupirfenidone could address a significant unmet need in the IPF treatment landscape, potentially capturing a substantial market share [1] - The findings may influence treatment guidelines and physician prescribing behavior, positioning Deupirfenidone as a preferred option for IPF management [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 As filed with the Securities and Exchange Commission on September 16, 2025 Registration No. 333- FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LYTUS TECHNOLOGIES HOLDINGS PTV. LTD. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 7841 Not applicable (State or Other Jurisdiction of (I.R.S. Employer Identification Number) LYTUS TECHNOLOGIES HOLDINGS PTV. LTD. Unit 504, Building 3 Studio City ...

Capital Structure and Share Issuance - The company amended its Memorandum and Articles to increase its authorized share capital from 230 million shares to 5 billion shares[144]. - The company issued 3.8 billion restricted common shares to the Lytus Trust for management and employee services[145]. - The company sold 965 million common shares at a price of $0.016 per share, generating gross proceeds of $15.44 million[146]. Business Expansion and Services - The company aims to expand its business by offering additional online services, targeting underserved areas in India due to low internet penetration[148]. - The company plans to enhance its service platform by investing in technology and expanding into new geographic markets[152]. - The company launched its Fintech business in 2023, focusing on converting cash collections into e-wallet payments and offering additional services like credit cards and microloans[166]. - The company is developing telemedicine solutions to address unmet medical needs in rural India, leveraging its existing fiber-optic network[163]. - The company is actively pursuing the provision of IPTV and broadband services to enhance revenue and customer loyalty, having obtained an Internet Service Provider License[384]. Financial Performance - Total revenue for the fiscal year ended March 31, 2024, was $23,003,342, representing a 19% increase from $19,393,329 in the previous year[335]. - Revenue from contracts with customers increased by $2,355,591 or 12%, totaling $21,363,775 for the fiscal year ended March 31, 2024[336]. - Subscription income grew by 7% to $14,955,197, while carriage/placement fees surged by 59% to $5,410,248[337]. - Other income saw a significant increase of 326%, reaching $1,639,567, primarily due to the reversal of finance costs related to warrants liability[336]. - Net income for the fiscal year ended March 31, 2024, was $1,439,610, a 33% increase from $1,078,491 in the previous year[332]. Cost Management - Cost of revenue increased by 21% to $16,762,580, reflecting the growth in operational scale[332]. - Interest expenses decreased by 71% to $638,957, down from $2,210,404, indicating improved financial management[332]. - Staffing expenses rose to $844,098 for the fiscal year ended March 31, 2024, reflecting an increase of $210,119 or 33% from $633,979 in 2023, primarily due to increased deployment of device boxes[344]. - Amortization and depreciation costs increased by $230,260 or 33% to $926,484 for the fiscal year ended March 31, 2024, attributed to additions in property, plant, and equipment[346]. Regulatory Compliance - The company is subject to extensive governmental laws and regulations in both the United States and India, particularly in the areas of streaming and telemedicine[192]. - The company must comply with the Cable Television Networks (Regulation) Act, 1995, which regulates the operation of cable television networks in India[196]. - The company is required to adhere to the Standards of Quality of Service (Digital Addressable Cable TV Systems) Regulations, 2012, ensuring timely responses to subscriber complaints[203]. - The company faces potential regulatory changes that could increase the regulatory burden on its products and services[192]. - The company must navigate complex state laws regarding the corporate practice of medicine and fee-splitting, which vary significantly and can lead to legal challenges[230]. Intellectual Property and Legal Matters - The company is in the process of registering its intellectual property rights to protect its business interests and competitive position[187]. - As of March 31, 2025, the company has applied for one trademark for the name "Lytus" and for two domain names in India and overseas[188]. - The company is not currently involved in any legal proceedings that are likely to have a material adverse effect on its business or financial position[190]. - The company is committed to protecting its technology and proprietary rights, although there are no assurances of success in these efforts[187]. Cash Flow and Financing Activities - Net cash provided by operating activities for the fiscal year ended March 31, 2024, was $886,034, a decrease from $1,153,335 in 2023[370]. - Net cash used in investing activities was $3,651,681 for the fiscal year ended March 31, 2024, compared to $12,920,014 in 2023[370]. - Net cash provided by financing activities was $2,705,230 for the fiscal year ended March 31, 2024, down from $11,655,402 in 2023[370]. - The company expects to utilize free cash flow and cash on hand for business growth, including potential mergers and acquisitions[366]. - The company plans to evaluate cash deployment for business growth, including potential mergers and acquisitions, stock repurchases, and dividends[381].

Core Insights - Lytus Technologies Holdings PTV. Ltd. reported significant revenue growth and improved profitability for the six months ended September 30, 2024, with a focus on innovation and operational efficiency [1][3] Financial Performance - Revenue for the six-month period reached $12.01 million, marking a 24% increase from $9.66 million in the same period of the previous year [5] - The company achieved a net profit of $648,972, reflecting a profit margin of 5.40%, which is a 151% increase compared to a net loss of $1,281,940 in the prior year [5] - Positive operating cash flow was generated amounting to $182,070 [5] Asset and Liability Management - Total assets increased to $34.17 million, an 8.3% rise from $31.56 million in the previous year [5] - Total liabilities decreased to $15.24 million, down 2.2% from $15.58 million in the same period last year [5] Strategic Initiatives - The company is expanding into broadband services, particularly in Telangana and Andhra Pradesh, which is expected to enhance revenue further [3] - Lytus Technologies has a captive base of 4 million subscribers and is focused on launching new value-added services to meet consumer and business demands [3][4]

Company Overview - Lytus Technologies Holdings, Ltd. has launched Lytus Healthcare, a fully owned subsidiary aimed at transforming patient care and healthcare accessibility in India [1][2] - The company is positioned to leverage its digital innovation strategy to enhance essential services for over 4 million users [2][10] Industry Growth - India's healthcare sector is projected to grow at a 22% CAGR, presenting significant opportunities for Lytus Healthcare to address service delivery gaps through AI-driven patient management solutions [2][3] Financial Performance - Lytus reported a 26% revenue growth for the first half of FY2025, driven by increased adoption of its digital platform services and strategic expansion efforts [3][4] - The company has secured an initial $6 million in funding under a Standby Equity Purchase Agreement (SEPA), with access to up to $100 million for growth capital over the next three years [4][5] Strategic Initiatives - Lytus is committed to sustainable growth while investing in next-generation solutions that enhance customer experience and shareholder value [4][5] - The company aims to deepen its presence in emerging markets and pioneer next-generation technology solutions across various sectors, including HealthTech, fintech, and AI [5][10]